Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Sector Investor who wrote (650)	12/22/1997 2:50:00 PM
From: Czechsinthemail	Respond to of 887

Michael King's comments on the side effects profile being skewed unfairly against DepoCyt were discussed by management during the conference call. They indicated that incidence of arachnoiditis were reduced by using steroids, but also that there may have been a reporting bias in noting virtually every detail on the experimental drug and possibly overlooking known side effects in the methotrexate group. Hopefully, DEPO will be able to establish both the efficacy of DepoCyt through larger numbers and the ability of steroids to moderate the side effects profile. For now, I think the assumption of a higher toxicity profile for DepoCyt compared with methotrexate remains uncertain. Baird

To: Sector Investor who wrote (650)	12/22/1997 5:36:00 PM
From: chirodoc	Read Replies (1) \| Respond to of 887

<<<<=DepoTech-3: Analyst: FDA Panel Assessment Not Entirely Fair .......it was not fair. but i'm still here feeling like an idiot holding 1,000 shares at a cost of $13.00. it was a tough lesson for this guy. i have never been caught in a downdraft like that. ......i am going to hold for at least 1 year with the hope that a lot of this SH#T will get cleared up with fda/chiron. also hoping for + depomorph results, although after seeing how mangement screwed up, i am not optmistic. this to me is now dead money.